ValuEngine upgraded shares of AtriCure (NASDAQ:ATRC) from a sell rating to a hold rating in a research note issued to investors on Wednesday.
A number of other brokerages have also weighed in on ATRC. Needham & Company LLC reaffirmed a buy rating and set a $23.00 target price (down from $25.00) on shares of AtriCure in a research report on Tuesday, January 16th. Canaccord Genuity increased their price target on AtriCure from $24.00 to $26.00 and gave the company a buy rating in a research report on Tuesday, February 27th. BidaskClub raised AtriCure from a sell rating to a hold rating in a research report on Friday, February 23rd. TheStreet lowered AtriCure from a c- rating to a d+ rating in a research report on Wednesday, November 29th. Finally, Piper Jaffray Companies reissued a buy rating and issued a $24.00 price target on shares of AtriCure in a research report on Sunday, December 10th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $24.67.
AtriCure (NASDAQ:ATRC) opened at $19.65 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.87 and a current ratio of 2.58. AtriCure has a 12-month low of $14.88 and a 12-month high of $25.18.
In related news, SVP Justin J. Noznesky sold 4,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total value of $68,120.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.
Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new position in AtriCure in the 3rd quarter valued at $771,000. Skylands Capital LLC bought a new position in AtriCure in the 4th quarter valued at $1,368,000. Wells Fargo & Company MN grew its stake in AtriCure by 35.8% in the 3rd quarter. Wells Fargo & Company MN now owns 51,683 shares of the medical device company’s stock valued at $1,156,000 after purchasing an additional 13,619 shares during the period. State Street Corp grew its stake in AtriCure by 4.0% in the 2nd quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock valued at $14,971,000 after purchasing an additional 23,790 shares during the period. Finally, Vanguard Group Inc. grew its stake in AtriCure by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock valued at $35,083,000 after purchasing an additional 52,761 shares during the period. Hedge funds and other institutional investors own 87.61% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/03/11/atricure-atrc-lifted-to-hold-at-valuengine.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.